Sbir phase 1: antibody array for cancer detection (topic 236)

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200800020C
Awardee
Awarding agency
Obligated
$150,000

Award facts

Opportunity
  • N43CN8500355 Solicitation number
Contract value 100% obligated
$150,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 12 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Monmouth Junction, South Brunswick Township, NJ 08852, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

About this award

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pharmaseq, Inc. The contract is for the development of an "Antibody Array for Cancer Detection" under SBIR Topic 236. The contract has a firm fixed price ceiling value of $150,000.00 and a period of performance ending on March 29, 2009. The contract is designated as a Total Small Business Set-Aside.

Quick answers

Who was awarded contract HHSN261200800020C?

HHSN261200800020C was awarded to Pharmaseq, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2008.

How much is contract HHSN261200800020C worth?

The government has obligated $150,000 on HHSN261200800020C.

Was contract HHSN261200800020C competed?

The extent of competition for HHSN261200800020C was full and open competition after exclusion of sources. The government received 12 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award